Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ALN-ANG3 · 2 trials · 2 indications
In participants treated with ALN-ANG3 or placebo (PBO)
In participants treated with ALN-ANG3 or PBO
| Arm | Type | Description |
|---|---|---|
| ALN-ANG3 + evinacumab placebo | EXPERIMENTAL | - |
| ALN-ANG3 + evinacumab | EXPERIMENTAL | - |
| ALN-ANG3 placebo + evinacumab placebo | PLACEBO_COMPARATOR | - |
| Part A: Cohorts | EXPERIMENTAL | - |
| Part B: Cohorts | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| ALN-ANG3 | DRUG | Administered per the protocol |
| Evinacumab | DRUG | Administered per the protocol |
| ALN-ANG3 placebo | DRUG | Administered per the protocol |
| Evinacumab placebo | DRUG | Administered per the protocol |
| Placebo (PB) | DRUG | Administered per the protocol |
Key Inclusion Criteria: 1. Medical history of type 2 diabetes and receiving medical therapy or lifestyle interventions for glucose management 2. Hemoglobin A1C (HbA1c) of 6.5 to 10% at screening 3. eGFR 30 to 90 mL/min/1.73 m\^2 using 2021 Chronic Kidney Disease-Epidemiology Collaboration-Estimated...
ALN-ANG3 is an investigational small molecule being developed for Diabetic Kidney Disease (DKD) and for healthy volunteers with hyperlipidemia. It is currently in Phase 2 clinical development for DKD and is also being studied in a Phase 1 trial in healthy adults with hyperlipidemia.
ALN-ANG3 targets angiopoietin-like protein 3 (ANGPTL3), as indicated by the Phase 2 trial title. The drug is designed to inhibit ANGPTL3, which is being studied for its effects in adult participants with Diabetic Kidney Disease.
ALN-ANG3 is being developed by Regeneron Pharmaceuticals, Inc., which trades under the ticker REGN. The company is conducting clinical trials to evaluate the safety and efficacy of ALN-ANG3 in Diabetic Kidney Disease and hyperlipidemia.
ALN-ANG3 is in Phase 2 clinical development for Diabetic Kidney Disease, with a Phase 2 trial currently recruiting participants. It is also being studied in a Phase 1 trial in healthy volunteers with hyperlipidemia. ALN-ANG3 is investigational and not yet approved.
ALN-ANG3 is being studied in two clinical trials: NCT06452771, a Phase 1 first-in-human study in healthy adults with hyperlipidemia in New Zealand, and NCT07271186, a Phase 2 study in adults with Diabetic Kidney Disease in the United States. Both trials are active.
ALN-ANG3 is an investigational drug that inhibits angiopoietin-like protein 3 (ANGPTL3), as described in the Phase 2 trial title. It is not referred to by any other name in the available information, and it is being studied for its effects on ANGPTL3 in Diabetic Kidney Disease.